UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2019-08, Vol.24 (8), p.1095-1102

2019

Volltextzugriff (PDF)

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

European journal of pharmacology, 2024-08, Vol.977, p.176725, Article 176725

2024

Volltextzugriff (PDF)

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Cancer and metastasis reviews, 2017-03, Vol.36 (1), p.141-157

2017

Volltextzugriff (PDF)

Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers

Journal of thoracic oncology, 2021-07, Vol.16 (7), p.1149-1165

2021

Volltextzugriff (PDF)

Fabrication and investigation potential effect of lentinan and docetaxel nanofibers for synergistic treatment of breast cancer in vitro

Polymers for advanced technologies, 2022-05, Vol.33 (5), p.1468-1480

2022

Volltextzugriff (PDF)

Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways

International journal of biological macromolecules, 2023-09, Vol.248, p.125867-125867, Article 125867

2023

Volltextzugriff (PDF)

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Frontiers in immunology, 2024, Vol.15, p.1376045-1376045

2024

Volltextzugriff (PDF)

A human epidermal growth factor receptor 3/heregulin interaction inhibitor aptamer discovered using SELEX

Biochemical and biophysical research communications, 2021-05, Vol.553, p.148-153

2021

Volltextzugriff (PDF)

Zebrafish her3 knockout impacts developmental and cancer-related gene signatures

Developmental biology, 2023-04, Vol.496, p.1-14

2023

Volltextzugriff (PDF)

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Cancer reports, 2024-03, Vol.7 (3), p.e1954-n/a

2024

Volltextzugriff (PDF)

Novel ex vivo disease model for extramammary Paget’s disease using the cancer tissue-originated spheroid method

Journal of dermatological science, 2020-09, Vol.99 (3), p.185-192

2020

Volltextzugriff (PDF)

An auristatin‐based antibody‐drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer

International journal of cancer, 2019-10, Vol.145 (7), p.1838-1851

2019

Volltextzugriff (PDF)

Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors

Journal of clinical pharmacology, 2023-01, Vol.63 (1), p.77-90

2023

Volltextzugriff (PDF)

Enzyme Is the Name-Adapter Is the Game

Cells (Basel, Switzerland), 2024-08, Vol.13 (15), p.1249

2024

Volltextzugriff (PDF)

The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients

Frontiers in pharmacology, 2020-08, Vol.11, p.537265-537265

2020

Volltextzugriff (PDF)

Targeting HER3 to overcome EGFR TKI resistance in NSCLC

Frontiers in immunology, 2024-01, Vol.14, p.1332057-1332057

2024

Volltextzugriff (PDF)

Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma

Cancer, 2015-10, Vol.121 (20), p.3600-3611

2015

Volltextzugriff (PDF)

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma

Translational lung cancer research, 2023-06, Vol.12 (6), p.1245-1255

2023

Volltextzugriff (PDF)

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

Cancer, 2016-12, Vol.122 (24), p.3803-3811

2016

Volltextzugriff (PDF)

NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis

Trends in Cancer, 2022-03, Vol.8 (3), p.242-258

2022

Volltextzugriff (PDF)

Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma

Journal of translational medicine, 2021-09, Vol.19 (1), p.408-408, Article 408

2021

Volltextzugriff (PDF)

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

Clinical cancer research, 2009-09, Vol.15 (17), p.5445-5456

2009

Volltextzugriff (PDF)

Development of recombinant biomimetic nano-carrier for targeted gene transfer to HER3 positive breast cancer

International journal of biological macromolecules, 2021-10, Vol.189, p.948-955

2021

Volltextzugriff (PDF)

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study

Translational lung cancer research, 2021-08, Vol.10 (8), p.3659-3670

2021

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Aktive Filter

ThemaHer3

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(80)

Erscheinungsjahr

n.n

Thema

Science & Technology
(69)
Life Sciences & Biomedicine
(68)
Humans
(47)
Oncology
(41)
Female
(25)
Breast Cancer
(23)
Receptor, Erbb-3 - Metabolism
(19)
Receptor, Erbb-2 - Metabolism
(17)
Human Epidermal Growth Factor Receptor 3
(15)
Animals
(14)
Cell Line, Tumor
(14)
Receptor, Erbb-3 - Genetics
(14)
Epidermal Growth Factor
(13)
Tumors
(13)
Cancer Therapies
(12)
Monoclonal Antibodies
(12)
Biochemistry & Molecular Biology
(11)
Cancer
(11)
Heregulin
(11)
Gene Expression
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers

Fabrication and investigation potential effect of lentinan and docetaxel nanofibers for synergistic treatment of breast cancer in vitro

Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

A human epidermal growth factor receptor 3/heregulin interaction inhibitor aptamer discovered using SELEX

Zebrafish her3 knockout impacts developmental and cancer-related gene signatures

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Novel ex vivo disease model for extramammary Paget’s disease using the cancer tissue-originated spheroid method

An auristatin‐based antibody‐drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer

Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors

Enzyme Is the Name-Adapter Is the Game

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients

Targeting HER3 to overcome EGFR TKI resistance in NSCLC

Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis

Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

Development of recombinant biomimetic nano-carrier for targeted gene transfer to HER3 positive breast cancer

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study

Aktive Filter

Suchergebnisse filtern